Fluoxetine, an antidepressant, suppresses glioblastoma by evoking AMPAR-mediated calcium-dependent apoptosis

Oncotarget

Volumn 6, Issue 7, 2015, Pages 5088-5101

  Liu, Kao Hui ^a   Yang, Shun Tai ^b   Lin, Yen Kuang ^c   Lin, Jia Wei ^b   Lee, Yi Hsuan ^d   Wang, Jia Yi ^a   Hu, Chaur Jong ^e   Lin, En Yuan ^f   Chen, Shu Mei ^c   Then, Chee Kin ^e   Shen, Shing Chuan ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

AMPA receptor; Antidepressant; Excitotoxicity; Glioblastoma

Indexed keywords

AMPA RECEPTOR; ANTIDEPRESSANT AGENT; CALCIUM ION; FLUOXETINE; TEMOZOLOMIDE; ALPHA-AMINO-3-HYDROXY-5-METHYLISOXAZOLE-4-PROPIONIC ACID SUBTYPE GLUTAMATE RECEPTOR, HUMAN; CALCIUM; GLUTAMATE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN MITOCHONDRION; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CANCER INHIBITION; CELL MEMBRANE TRANSPORT; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; GLIOBLASTOMA; GLIOMA CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RAT; ANIMAL; BRAIN NEOPLASMS; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; METABOLISM; MOLECULAR DOCKING; NUDE MOUSE; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; APOPTOSIS; BRAIN NEOPLASMS; CALCIUM; CELL SURVIVAL; FLUOXETINE; GLIOBLASTOMA; HUMANS; MALE; MICE; MICE, NUDE; MOLECULAR DOCKING SIMULATION; RECEPTORS, GLUTAMATE; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84925004161     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3243     Document Type: Article

References (50)

1. Preusser M, de Ribaupierre S, Wohrer A, Erridge SC, Hegi M, Weller M and Stupp R. Current concepts and management of glioblastoma. Ann Neurol. 2011; 70: 9-21.
2. Huang YC, Wei KC, Chang CH, Yang JT, Ho JT, Shen CC, Su CF, Cho DY, Ma HI, Lin JW, Lee EJ, Wu JJ, Tsai MD, Chang CK, Howng SL and Chang CN. A retrospective survey of patients with malignant gliomas treated in the neuro-oncological care system under the Universal National Health Insurance program in Taiwan. J Clin Neurosci. 2011; 18: 784-788.
3. Norden AD and Wen PY. Glioma therapy in adults. Neurologist. 2006; 12: 279-292.
4. Park DM, Sathornsumetee S and Rich JN. Medical oncology: treatment and management of malignant gliomas. Nat Rev Clin Oncol. 2010; 7: 75-77.
5. Blakeley J. Drug delivery to brain tumors. Curr Neurol Neurosci Rep. 2008; 8: 235-241.
6. Siegal T. Which drug or drug delivery system can change clinical practice for brain tumor therapy? Neuro Oncol. 2013; 15: 656-669.
7. Li YM and Hall WA. Cell surface receptors in malignant glioma. Neurosurgery. 2011; 69: 980-994.
8. Sathornsumetee S and Rich JN. Designer therapies for glioblastoma multiforme. Ann N Y Acad Sci. 2008; 1142: 108-132.
9. de Groot J and Sontheimer H. Glutamate and the biology of gliomas. Glia. 2011; 59: 1181-1189.
10. Rzeski W, Ikonomidou C and Turski L. Glutamate antagonists limit tumor growth. Biochem Pharmacol. 2002; 64: 1195-1200.
11. Takano T, Lin JH, Arcuino G, Gao Q, Yang J and Nedergaard M. Glutamate release promotes growth of malignant gliomas. Nat Med. 2001; 7: 1010-1015.
12. Clapham DE. Calcium signaling. Cell. 2007; 131: 1047-1058.
13. Trump BF and Berezesky IK. Calcium-mediated cell injury and cell death. FASEB J. 1995; 9: 219-228.
14. Smaili S, Hirata H, Ureshino R, Monteforte PT, Morales AP, Muler ML, Terashima J, Oseki K, Rosenstock TR, Lopes GS and Bincoletto C. Calcium and cell death signaling in neurodegeneration and aging. An Acad Bras Cienc. 2009; 81: 467-475.
15. Pinton P, Giorgi C, Siviero R, Zecchini E and Rizzuto R. Calcium and apoptosis: ER-mitochondria Ca2+ transfer in the control of apoptosis. Oncogene. 2008; 27: 6407-6418.
16. Chien JM, Chou CT, Pan CC, Kuo CC, Tsai JY, Liao WC, Kuo DH, Shieh P, Ho CM, Chu ST, Su HH, Chi CC and Jan CR. The mechanism of sertraline-induced [Ca2+]i rise in human OC2 oral cancer cells. Hum Exp Toxicol. 2011; 30: 1635-1643.
17. Huang JK, Chang HT, Chou CT, Shu SS, Kuo CC, Tsai JY, Liao WC, Wang JL, Lin KL, Lu YC, Chen IS, Liu SI, Ho CM and Jan CR. The mechanism of sertraline-induced [Ca(2+) ](i) rise in human PC3 prostate cancer cells. Basic Clin Pharmacol Toxicol. 2011; 109: 103-110.
18. Tang KY, Cheng JS, Lee KC, Chou KJ, Huang JK, Chen WC and Jan CR. Fluoxetine-induced Ca2+ signals in Madin-Darby canine kidney cells. Naunyn Schmiedebergs Arch Pharmacol. 2001; 363: 16-20.
19. Karson CN, Newton JE, Livingston R, Jolly JB, Cooper TB, Sprigg J and Komoroski RA. Human brain fluoxetine concentrations. J Neuropsychiatry Clin Neurosci. 1993; 5: 322-329.
20. Henry ME, Schmidt ME, Hennen J, Villafuerte RA, Butman ML, Tran P, Kerner LT, Cohen B and Renshaw PF. A comparison of brain and serum pharmacokinetics of R-fluoxetine and racemic fluoxetine: A 19-F MRS study. Neuropsychopharmacology. 2005; 30: 1576-1583.
21. Kornhuber J, Reichel M, Tripal P, Groemer TW, Henkel AW, Muhle C and Gulbins E. The role of ceramide in major depressive disorder. Eur Arch Psychiatry Clin Neurosci. 2009; 259 Suppl 2: S199-204.
22. Mukherjee J, Das MK, Yang ZY and Lew R. Evaluation of the binding of the radiolabeled antidepressant drug, 18F-fluoxetine in the rodent brain: an in vitro and in vivo study. Nucl Med Biol. 1998; 25: 605-610.
23. Sobolevsky AI, Rosconi MP and Gouaux E. X-ray structure, symmetry and mechanism of an AMPA-subtype glutamate receptor. Nature. 2009; 462: 745-756.
24. Dingledine R, Borges K, Bowie D and Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev. 1999; 51: 7-61.
25. Zhou R, Holmes A, Du J, Malkesman O, Yuan P, Wang Y, Damschroder-Williams P, Chen G, Guitart X and Manji HK. Genome-wide gene expression profiling in GluR1 knockout mice: key role of the calcium signaling pathway in glutamatergically mediated hippocampal transmission. Eur J Neurosci. 2009; 30: 2318-2326.
26. Shepherd JD and Huganir RL. The cell biology of synaptic plasticity: AMPA receptor trafficking. Annu Rev Cell Dev Biol. 2007; 23: 613-643.
27. Abdul M, Logothetis CJ and Hoosein NM. Growth-inhibitory effects of serotonin uptake inhibitors on human prostate carcinoma cell lines. J Urol. 1995; 154: 247-250.
28. Levkovitz Y, Gil-Ad I, Zeldich E, Dayag M and Weizman A. Differential induction of apoptosis by antidepressants in glioma and neuroblastoma cell lines: evidence for p-c-Jun, cytochrome c, and caspase-3 involvement. J Mol Neurosci. 2005; 27: 29-42.
29. Tzadok S, Beery E, Israeli M, Uziel O, Lahav M, Fenig E, Gil-Ad I, Weizman A and Nordenberg J. In vitro novel combinations of psychotropics and anti-cancer modalities in U87 human glioblastoma cells. Int J Oncol. 2010; 37: 1043-1051.
30. Blagosklonny MV. A new science-business paradigm in anticancer drug development. Trends Biotechnol. 2003; 21: 103-106.
31. Triscott J, Lee C, Hu K, Fotovati A, Berns R, Pambid M, Luk M, Kast RE, Kong E, Toyota E, Yip S, Toyota B and Dunn SE. Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide. Oncotarget. 2012; 3: 1112-1123.
32. Kast RE, Karpel-Massler G and Halatsch ME. CUSP9*treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide. Oncotarget. 2014; 5: 8052-8082.
33. Kast RE, Boockvar JA, Bruning A, Cappello F, Chang WW, Cvek B, Dou QP, Duenas-Gonzalez A, Efferth T, Focosi D, Ghaffari SH, Karpel-Massler G, Ketola K, Khoshnevisan A, Keizman D, Magne N, et al. A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. Oncotarget. 2013; 4: 502-530.
34. Xu W, Tamim H, Shapiro S, Stang MR and Collet JP. Use of antidepressants and risk of colorectal cancer: a nested case-control study. Lancet Oncol. 2006; 7: 301-308.
35. Walker AJ, Card T, Bates TE and Muir K. Tricyclic antidepressants and the incidence of certain cancers: a study using the GPRD. Br J Cancer. 2011; 104: 193-197.
36. Suchard JR. Fluoxetine overdose-induced seizure. West J Emerg Med. 2008; 9: 154-156.
37. Lydiatt WM, Denman D, McNeilly DP, Puumula SE and Burke WJ. A randomized, placebo-controlled trial of citalopram for the prevention of major depression during treatment for head and neck cancer. Archives of Otolaryngology-Head & Neck Surgery. 2008; 134: 528-535.
38. Roscoe JA, Morrow GR, Hickok JT, Mustian KM, Griggs JJ, Matteson SE, Bushunow P, Qazi R and Smith B. Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat. 2005; 89: 243-249.
39. Caudill JS, Brown PD, Cerhan JH and Rummans TA. Selective serotonin reuptake inhibitors, glioblastoma multiforme, and impact on toxicities and overall survival: the mayo clinic experience. Am J Clin Oncol. 2011; 34: 385-387.
40. Ishiuchi S, Yoshida Y, Sugawara K, Aihara M, Ohtani T, Watanabe T, Saito N, Tsuzuki K, Okado H, Miwa A, Nakazato Y and Ozawa S. Ca2+-permeable AMPA receptors regulate growth of human glioblastoma via Akt activation. J Neurosci. 2007; 27: 7987-8001.
41. Svenningsson P, Tzavara ET, Witkin JM, Fienberg AA, Nomikos GG and Greengard P. Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc Natl Acad Sci U S A. 2002; 99: 3182-3187.
42. Weiss JH. Ca permeable AMPA channels in diseases of the nervous system. Front Mol Neurosci. 2011; 4: 42.
43. Kamar FG and Posner JB. Brain metastases. Semin Neurol. 2010; 30: 217-235.
44. Lin MS, Sun YY, Chiu WT, Hung CC, Chang CY, Shie FS, Tsai SH, Lin JW, Hung KS and Lee YH. Curcumin attenuates the expression and secretion of RANTES after spinal cord injury in vivo and lipopolysaccharide-induced astrocyte reactivation in vitro. Journal of neurotrauma. 2011; 28(7):1259-1269.
45. Grynkiewicz G, Poenie M and Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1985; 260: 3440-3450.
46. Bravman T, Bronner V, Lavie K, Notcovich A, Papalia GA and Myszka DG. Exploring "one-shot" kinetics and small molecule analysis using the ProteOn XPR36 array biosensor. Anal Biochem. 2006; 358: 281-288.
47. Munoz EM, Correa J, Riguera R and Fernandez-Megia E. Real-time evaluation of binding mechanisms in multivalent interactions: a surface plasmon resonance kinetic approach. J Am Chem Soc. 2013; 135: 5966-5969.
48. Arnold K, Bordoli L, Kopp J and Schwede T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics. 2006; 22: 195-201.
49. Bordoli L, Kiefer F, Arnold K, Benkert P, Battey J and Schwede T. Protein structure homology modeling using SWISS-MODEL workspace. Nat Protoc. 2009; 4: 1-13.
50. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS and Olson AJ. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009; 30: 2785-2791.